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Purpose. The aim of the study was to assess the in vitro 
potency of pentoxifylline (PTX) and one of its most ac-
tive metabolites lisofylline (LSF) to improve rheological 
properties of red blood cells (RBC) from healthy individu-
als and patients with chronic venous disease (CVD). Ad-
ditionally, the study aimed to compare the effects of PTX 
and LSF on RBC deformability and aggregation. Meth-
ods. Blood samples were collected from healthy volun-
teers (antecubital vein) and from CVD patients (varicose 
and antecubital vein). Deformability and aggregation 
of RBC were assessed using Laser-assisted Optical Ro-
tational Cell Analyser (LORCA). Results. PTX and LSF in-
creased RBC elongation significantly. Additionally, RBC 
incubation with PTX resulted in a marked decrease in 
RBC aggregation. PTX reduced the tendency towards the 
formation of RBC aggregates and of their stability. The 
beneficial effect of PTX on RBC aggregation was most 
apparent for those cells whose aggregation tendency 
and aggregate stability was the greatest. Conclusions. In 
vitro addition of PTX or LSF effectively increased deform-
ability of RBC from healthy donors and patients with 
CVD. Thus, LSF may contribute to the in vivo hemorheo-
logical effects of pentoxifylline. On the other hand, there 
was no significant effect of LSF on aggregation of RBC in 
vitro. Hence, LSF has no contribution to this particular 
effect of PTX. Additionally, the present study demon-
strated the use of RBC with impaired deformability and 
aggregation for the evaluation of in vitro rheological ac-
tivity of xenobiotics.
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INTRODUCTION
Pentoxifylline (PTX) is a xanthine derivative and a 
nonspecific inhibitor of cyclic adenosine monophosphate 
(AMP) phosphodiesterases, widely used in daily clinical 
practice for treatment of various cerebrovascular and pe-
ripheral vascular diseases characterized by a defective tis-
sue perfusion (Moher et al., 2000; Jull et al., 2002). The 
therapeutic effect of PTX is related mainly to its ability 
to improve microvascular blood flow. The compound 
has been reported to increase flexibility of red blood cells 
(RBC) and to decrease blood viscosity (Muller, 1981; Ott 
et al. 1983; Eun et al., 2000). Additionally, it was dem-
onstrated that PTX reduces RBC aggregation (Accetto, 
1982). As a hemorheological agent the compound acts 
also by decreasing the potential for platelet aggregation 
and thrombus formation (Frampton & Brodgen, 1995).
Several studies have been conducted to investigate 
the action of PTX in vitro and in vivo on hemorheol-
ogy. However, no in vivo effect of PTX or its metabo-
lites on RBC rheology has been found. Thus, the aim 
of the present study was to assess the in vitro potency 
of pentoxifylline and one of its most active metabo-
lites, lisofylline (LSF), to improve rheological proper-
ties of erythrocytes from healthy individuals (antecu-
bital vein) and patients with chronic venous disease 
(CVD) (antecubital vein and varicose vein), and to 
compare the effects of PTX and LSF on RBC de-
formability and aggregation.
MATERIALS AND METHODS
Blood samples. Blood samples were collected from 
healthy volunteers (n = 30; mean age 39.46 ± 15.23 
years) and from CVD patients with varicosis (n = 26; 
mean age 44.64 ±   14.75 years) via withdrawal into po-
tassium EDTA (ethylenediaminetetraacetic acid) con-
taining tubes. The patients were rated as having le-
sions of CVD levels II and III according to clinical 
features included in the CEAP (clinical, etiological, 
anatomical and pathological elements) classification.
The patients considered for the study were those at-
tending the 2nd Chair of General Surgery of the Jagiel-
lonian University Medical College for the management 
of venous disease. The diagnosis of primary varicose 
vein was based on the clinical examination and duplex 
scanning examination. The patients had a positive 
family history of CVD and the symptoms of the dis-
ease had been observed for more than one year. Ad-
ditionally, all patients showed normal fibrinogen level. 
Patients had not taken any medication within the last 
two weeks prior to blood withdrawal. Blood was col-
lected from antecubital veins of healthy subjects and 
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from antecubital veins and varicose veins of CVD pa-
tients. All volunteers gave their informed consent pri-
or to donating their blood. The study was approved 
by the Commission of Bioethics of the Jagiellonian 
University.
Reagents. PTX was purchased from Sigma. LSF 
was obtained through enantioselective reduction of 
PTX using whole-cell Lactobacillus kefiri according to 
Pękala et al. (2007). All drugs were diluted with phos-
phate buffered saline (PBS).
Incubation with drugs. The blood samples were 
centrifuged (1400 × g, 5 min, 4°C), blood plasma was 
removed and the remaining erythrocytes were washed 
3 times with PBS (pH = 7.4). The washed RBC were 
then re-suspended in autologous plasma at a hematocrit 
of 40% (Baskurt et al., 2009). RBC suspensions were di-
vided into aliquots and exposed to one of the drugs (at 
a final concentration of 10–4 and 10–5 M) or PBS (control 
sample) at 37°C for 30 minutes. The samples were incu-
bated with constant mixing in a water bath. After incu-
bation in the drug solution, RBC were washed as above 
and re-suspended in autologous plasma at a hematocrit 
of 40%. The morphology of RBC was evaluated using 
a Leica DM1000 microscope (Leica Microsystems) and 
RBC deformability and aggregation were assessed.
Deformability measurement. RBC deformability 
was measured with a Laser-assisted Optical Rotational 
Cell Analyser (LORCA, Mechatronics, The Nether-
lands), according to the methods of Hardeman et al. 
(1994 and 2001). Twenty-five ml of blood was diluted 
200 times with 0.14 mM polyvinylpyrrolidone (PVP, 
pH = 7.4, osmotic pressure 300 mOsm/kg, viscosity 
30 mPas, Sigma). RBC deformability was analyzed at a 
range of shear stresses (0.30–59.97 Pa) and expressed 
as elongation index (EI) of erythrocytes defined as 
EI = (A–B)/(A+B), where A and B are the long and 
short axes of the ellipse, respectively (Hardeman et al., 
1994). The higher the value of EI, the greater defor-
mation of blood cells.
Aggregation measurement. The aggregation of 
erythrocytes was also approached by LORCA. Ag-
gregation measurement was performed using 1 to 2 
ml blood. Erythrocytes were oxygenated for 10–15 
minutes before the measurement by slow rotation 
in a glass vessel. The aggregation measurement was 
based on the detection of laser back-scattering from 
sheared, then unsheared blood. RBC aggregation pa-
rameters were determined with a syllectogram, which 
is a curve illustrating the change in the light intensity 
of scattered light during 120 s corresponding to the 
process of aggregation (Hardeman et al., 2001). The 
following parameters of aggregation were studied: ag-
gregation index (AI), threshold shear rate (THR), and 
aggregation halftime (T½). AI characterizes the extent 
of RBC aggregation, T½ reflects aggregation kinetics 
whereas THR shows the tendency towards the forma-
tion of aggregates and their stability. An increase in 
THR means an increased tendency towards the forma-
tion of aggregates and of their stability. A drop in T½ 
parameter indicates a faster rate of aggregation (Har-
deman et al., 2001).
Statistical analysis and data presentation. Data 
are presented as means ± S.D. of n experiments. Com-
parisons of the effects of the investigated compounds 
on the RBC deformability and aggregation were made 
by statistical analysis of variance (ANOVA). The re-
sults were considered significant when p < 0.05. Tests 




In vitro studies showed that PTX and LSF in both 
concentrations tested increased the RBC elongation sig-
nificantly. Graphs depict only those shear stress values 
for which significant EI changes were observed. Incu-
bation of RBC from healthy adults and CVD patients 
with PTX led to EI increase vs control (Fig. 1A–C). 
In the case of erythrocytes from healthy donors, a sig-
nificant improvement of RBC elongation was stated 
for shear stresses: 1.13 (10–4 M 48.8% increase vs con-
trol, p < 0.01; 10–5 M 32.9% increase vs control, p < 0.01), 
2.19 (10–4 M 26.3% increase vs control, p < 0.001; 10–5 M 
18.9% increase vs control, p < 0.001), 4.24 (10–4 M 13% 
increase vs control, p < 0.01; 10–5 M 9% increase vs con-
trol, p < 0.01) and 8.23 Pa (10–4 M 10.7% increase vs con-
trol, p < 0.001; 10–5 M 7% increase vs control, p < 0.001) 
(Fig. 1A). In the case of RBC from the antecubital vein 
of CVD patients for shear stress values: 2.19 (17.8% 
at 10–4 M, p < 0.01 and 13.9% at 10–5 M, p < 0.01), 4.24 
(13.7% at 10–4 M, p < 0.01 and 9.5% at 10–5 M, p < 0.01) 
and 8.23 Pa (12.5% at 10-4 M, p < 0.001 and 7.4% at 10–5 
M, p < 0.001) (Fig. 1B). For the RBC from the varicose 
vein of CVD patients for shear stresses: 2.19 (21.8% 
at 10-4 M, p < 0.01 and 12.7% at 10-5 M, p < 0.01), 4.24 
(12.4% at 10–4 M, p < 0.01 and 8.4% at 10–5 M, p < 0.01) 
and 8.23 Pa (10.6% at 10–4 M, p < 0.01 and 6.9% at 10–5 
M, p < 0.01) (Fig. 1C). When comparing the deformabil-
ity results between healthy subjects and CVD patients it 
was found that the EI values obtained in the presence 
of PTX (in both concentrations tested) were significantly 
different (p < 0.05) for the two groups for shear stress 
values 1.13 and 8.23 Pa. For shear stresses 2.19 and 4.24 
Pa the differences were significant (p < 0.05) between 
RBC from healthy adults and the varicose vein of CVD 
patients.
The RBC derived from the three different sources and 
treated with LSF had improved deformability for shear 
stress values 4.24 and 8.23 Pa. In the case of healthy 
donors erythrocytes, a significant improvement of RBC 
elongation was found for shear stresses: 4.24 (10–4 M 
17% increase vs control, p < 0.01; 10–5 M 10% increase 
vs control, p < 0.01) and 8.23 (10–4 M 13.5% increase 
vs control, p < 0.001; 10–5 M 7% increase vs control, 
p < 0.001) (Fig. 2A). For the RBC from the antecubital 
vein of CVD patients for shear stress values: 4.24 (14% 
at 10–4 M, p < 0.001 and 8.8% at 10–5 M, p < 0.001) and 
8.23 Pa (10.7% at 10–4 M, p < 0.01 and 6.5% at 10-5 M, 
p < 0.01) (Fig. 2B). For the RBC from the varicose vein 
of CVD patients for shear stresses: 4.24 (12.1% at 10–4 
M, p < 0.01 and 8.4% at 10–5 M, p < 0.01) and 8.23 Pa 
(8.4% at 10–4 M, p < 0.01 and 6.2% at 10–5 M, p < 0.01) 
(Fig. 2C).
A comparison of the deformability results between 
healthy donors and patients showed that the EI values 
obtained in the presence of LSF (in both concentrations 
tested) differ significantly (p < 0.05) for shear stress 2.19 
Pa. At shear stress values 4.24 and 8.23 Pa the differ-
ences were significant (p < 0.05) between the RBC from 
healthy donors and the varicose vein of CVD patients.
RBC aggregation
Considering the aggregation measurements, PTX 
improved the RBC aggregation significantly. Incuba-
tion of healthy donors and CVD patients’ erythrocytes 
with PTX caused a significant decrease of AI (healthy 
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Figure 1. The influence of pentoxifylline (PTX) on RBC deform-
ability. 
RBC derived from: (A) antecubital vein of healthy donors; (B) an-
tecubital vein of CVD patients; (C) varicose vein of CVD patients. 
Data are given as means ± S.D. of n= 10 experiments. Significance 
vs control: *p < 0.05, **p < 0.01, ***p < 0.001; significance vs non-
incubated control: #p < 0.05, ##p < 0.01, ### p < 0.001.
Figure 2. The influence of lisofylline (LSF) on RBC deformability. 
RBC derived from: (A) antecubital vein of healthy donors; (B) an-
tecubital vein of CVD patients; (C) varicose vein of CVD patients. 
Data are given as means ± S.D. of n = 10 experiments. Significance 
vs control: *p < 0.05, **p < 0.01, ***p < 0.001; significance vs non-
incubated control: #p < 0.05, ##p < 0.01, ### p < 0.001.
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donors: –22.5% at 10–4 M, p < 0.01 and –17.3% at 10–5 
M, p < 0.01; CVD patients — antecubital vein: –22.7% 
at 10–4 M, p < 0.05 and –19% at 10–5 M, p < 0.05; CVD 
patients — varicose vein: –20.7% at 10–4 M, p < 0.01 and 
–13.9% at 10–5 M, p < 0.05) (Fig. 3A–C). A decrease in 
THR was observable after treatment of the RBC from 
healthy donors and CVD patients with either dosage 
of PTX (healthy donors: –13% at 10–4 M, p < 0.05 and 
Figure 3.The influence of pentoxifylline (PTX) and lisofylline (LSF) on RBC aggregation index (AI) and threshold shear rate (THR). 
RBC derived from: (A) and (D), antecubital vein of healthy donors; (B) and (E), antecubital vein of CVD patients; (C) and (F), varicose vein 
of CVD patients. Data are given as means ± S.D. of n= 10 experiments. Significance vs control: *p < 0.05,**p < 0.01, ***p < 0.001; signifi-
cance vs non-incubated control: #p < 0.05,##p < 0.01, ###p < 0.001. NC, non-incubated control; C, control.
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–10.7% at 10–5 M, p < 0.05; CVD patients — antecubi-
tal vein: –16% at 10–4 M, p < 0.05 and –7.1% at 10–5 M, 
p < 0.05; CVD patients – varicose vein: –23.1% at 10–4 
M, p < 0.01 and –16.8% at 10–5 M, p < 0.05) (Fig. 3D–F). 
A significant improvement of T½ was observed after in-
cubation with either PTX concentration only for RBC 
from the varicose vein of CVD patients (32.7% at 10–4 
M, p < 0.05 and 13.7% at 10–5 M, p < 0.05).
When comparing aggregation parameters between 
controls and CVD patients it was noted that AI values 
obtained in the presence of PTX (in lower concentration 
tested) differ significantly (p < 0.05) between the RBC 
from healthy adults and varicose vein of CVD patients. 
In case of THR significant differences (p < 0.05) were 
observed after incubation with PTX (higher concentra-
tion) between RBC from controls and antecubital vein 
of the patients. In case of lower PTX concentration sig-
nificant differences (p < 0.05) were noted between RBC 
from healthy donors and varicose vein samples. The 
same was found for LSF. Regarding T½ parameter, sta-
tistical significance (p < 0.05) was stated after incubation 
with higher PTX concentration between RBC from vari-
cose vein and antecubital vein of the patients. The same 
was observed for LSF.
DISCUSSION
The influence of PTX and one of its most active me-
tabolites LSF on the deformability and aggregation of red 
blood cells were investigated in vitro. RBC from healthy 
volunteers and patients with chronic venous disease were 
used in the study. An impairment of RBC rheological 
properties in CVD was previously reported (Boisseau & 
de La Giclais, 2004; Chwała et al., 2009). We decided to 
undertake an in vitro study because in vivo there is always 
a mixture of the parent compound and its metabolites 
after administration of PTX, which excludes the possibil-
ity of examining and comparing the compounds’ activity 
separately. Although PTX is metabolized in RBC (Ings et 
al., 1982; Nicklasson et al., 2002), the extent of this phe-
nomenon is rather negligible due to the short duration 
of the in vitro experiment.
The present study showed that incubation of RBC 
with PTX or LSF led to a marked increase of their de-
formability. PTX significantly improved the deformabili-
ty of erythrocytes from CVD patients for three values  of 
shear stress, 2.19, 4.24 and 8.23 Pa, whereas for the RBC 
from healthy controls also for shear stress of 1.13 Pa. 
Thus, PTX had better rheological effects on erythrocytes 
from healthy controls than in those from CVD subjects. 
At the same time LSF enhanced the deformability for 
all RBC tested for shear stress values of 4.24 and 8.23 
Pa. Chwała et al. (2009) demonstrated previously that de-
formability of RBC was higher in subjects suffering from 
venous disease than in healthy controls. In the present 
study the beneficial effects of PTX on RBC deformabil-
ity were greater in erythrocytes whose deformability was 
lower. It was shown previously that the improvement of 
RBC deformability by PTX can be attributed primarily 
to the increase of adenosine triphosphate (ATP) content 
in RBC (Stefanovich, 1975). ATP is required to maintain 
the unique biomechanical properties of the RBC mem-
brane (Nakao et al., 1960).
The obtained results are in good agreement with data 
obtained by previous investigators who examined the ef-
fect of PTX on RBC with impaired deformability. Le-
onhardt and Grigoleit (1977) showed that PTX addition 
improved RBC deformability under hyperosmolar condi-
tions. Comparable results were obtained by Ehrly (1979). 
Seiffge and Kiesewetter (1981) investigated the effect 
of PTX on single red cell deformability. Those authors 
showed that PTX addition to a Ca2+-treated red cell 
suspension reduced the medium passage time through 
a singlepore membrane under a driving pressure gradi-
ent. Additionally, Singh and Kumaravel (1996) confirmed 
that PTX increased the deformability of normal erythro-
cytes under in vitro conditions.
On the other hand, our results are in contrast to 
those obtained by Cummings and Ballas (1990), who ex-
amined the in vitro effect of PTX and its major hydrox-
yhexyl metabolite on RBC deformability. Erythrocytes 
were obtained from healthy volunteers and patients with 
sickle cell disease and incubated with different concen-
trations of drugs for varying time periods. Those authors 
demonstrated no effect on the erythrocyte deformability 
of either compound at any concentration or incubation 
time period. The discrepancy between our results and 
those of Cummings and Ballas (1990) may be attrib-
uted primarily to the nature and origin of the diseased 
RBC used in the two experiments (sickle cell disease vs 
chronic venous disease) but also to methodology (e.g., 
temperature of incubation, number of participants). Ad-
ditionally, the applied measurement techniques and ana-
lyzed parameters are not fully comparable. Moreover, the 
earlier authors could not distinguish between the enanti-
omers of metabolite 1 (M1), which differ significantly in 
their potencies.
In the present study a beneficial influence of the 
compounds tested on the RBC deformability was noted 
only at low and medium shear stress (mainly 2.19–8.23 
Pa). At the other values of shear stress the EI value did 
not differ significantly between control RBC and those 
treated with a drug. The shear rate is determined by the 
diameter of the vessel and the highest shear rates are ob-
served in the smallest vessels. In large vessels RBC elon-
gate in response to shear forces, while in the microcir-
culation erythrocytes squeeze through capillaries. Hence, 
the RBC deformability is measured at a range of shear 
rates. In the elongation index vs shear stress curve the 
initial part of the curve represents the rigidity of the cell 
membrane (Hardemann & Ince, 1999). In the present 
study this part of the curve was significantly affected, 
thus the observed alternations in RBC deformability may 
be caused by changes in the RBC membrane.
The present study showed that incubation of RBC 
with PTX resulted in a marked decrease of their aggre-
gation (Fig. 3A–C). These findings are consistent with 
earlier results obtained by Muravyov et al. (2007), who 
examined in vitro hemorheological efficiency of drugs 
targeting intracellular phosphodiesterase activity. It was 
found that PTX significantly decreased normal red cell 
aggregation. In the present study the decrease was com-
parable for erythrocytes from the antecubital vein of 
healthy donors and varicose vein of the patients and was 
about 22,5% at the higher concentration of PTX tested. 
Additionally, PTX reduced the tendency of RBC from 
all sources used in the experiments to form aggregates 
and their stability (Fig. 3D–F). It can be seen, however, 
that the beneficial effect of PTX on RBC aggregation 
was most apparent for those cells whose aggregation 
tendency and aggregate stability were the greatest (RBC 
from the varicose vein of CVD patients). Furthermore, 
PTX significantly decreased the rate of aggregation (T½ 
analysis) of RBC from the varicose veins. This confirms 
earlier data suggesting that RBC with an impaired aggre-
gation and deformability (due to a disease) may be useful 
for the in vitro evaluation of the rheological activity of 
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xenobiotics (Dintenfass, 1983; Salbaş et al., 1993; Lipo-
vac et al., 2000).
The mechanism responsible for the beneficial influ-
ence of PTX on RBC aggregation may be related to 
the improvement of RBC deformability (Seiffge, 1982). 
Moreover, PTX has been reported to reduce fibrino-
gen level (Angelkort & Kiesewetter, 1981; Perego et al., 
1983). The presence of large plasma proteins such as fi-
brinogen is the major cause of aggregation (Skalak et al., 
1981; Marton et al., 2001).
Concerning earlier studies on the in vivo effect of PTX 
on RBC rheological properties, Schneider (1989) exam-
ined the hemorheological effects of PTX treatment in 
patients with cerebrovascular disease. The study showed 
that in patients who received PTX parenterally eryth-
rocyte aggregation did not change significantly whereas 
there was a marked improvement in RBC deformabil-
ity and yield shear stress. Additionally, during oral PTX 
treatment the hemorheologic variables, which were 
pathologically altered at baseline, improved significantly. 
Dawson et al. (2002) evaluated hemorheologic effects of 
PTX and cilostazol administered to adults with moderate 
to severe claudication on the viscosity, fibrinogen level 
and RBC deformability. Those authors concluded that 
ex vivo rheologic characteristics of blood from patients 
with intermittent claudication were not significantly af-
fected by long-term administration of PTX or cilostazol. 
Additionally, PTX did not modulate RBC deformability. 
Studies on the efficacy of pentoxifylline treatment indi-
cate that clinical improvement becomes apparent usually 
two to four weeks after the first oral dose. It follows 
that the drug should be administered for at least four 
weeks and discontinued if there is no clinical improve-
ment. This time period appears to be necessary for rec-
ompensation of the patho-hemorheologic abnormality in 
ischemic tissue (Aviado & Dettelbach, 1984).
Regarding the effects of PTX and its metabolite on 
RBC deformability and aggregation, PTX is rapidly me-
tabolized to a variety of metabolites, denoted M1–M7. 
After oral or intravenous administration of PTX to 
healthy volunteers, the plasma levels of metabolite 1 
(M1) (including LSF) as well as metabolite 5 (M5) sig-
nificantly exceeded the level of the parent drug (Beer-
man et al., 1985; Nicklasson et al., 2002). The present in 
vitro study showed that LSF significantly improved the 
deformability of erythrocytes and may thus contribute 
to the in vivo haemorheological effects of pentoxifylline. 
These results are in good agreement with data obtained 
by Ambrus et al. (1995), who demonstrated that M1 and 
M5 are similar to PTX in their activity on RBC mem-
brane fluidity. In contrast, we found no significant effect 
of LSF on the aggregation of RBC in vitro. Thus, LSF 
has no contribution to this particular effect of the par-
ent compound. It is plausible that the effects of PTX 
on erythrocyte aggregation are due to the activity of the 
other metabolites.
In summary, it was demonstrated that in vitro addition 
of PTX or LSF effectively increased deformability of 
RBC from healthy donors and patients with CVD. Thus, 
LSF may contribute to the in vivo hemorheological ef-
fects of pentoxifylline. On the other hand, there was no 
significant effect of LSF on aggregation of RBC in vitro. 
Hence, LSF has no contribution to this particular effect 
of the parent compound. Additionally, the present study 
demonstrated the usefulness of RBC with impaired de-
formability and aggregation for the evaluation of in vitro 
rheological activity of xenobiotics.
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